CVS Health Corp (CVS)
66.97
-0.88 (-1.30%)
NYSE · Last Trade: May 10th, 1:36 PM EDT
Detailed Quote
Previous Close | 67.85 |
---|---|
Open | 67.73 |
Bid | 66.85 |
Ask | 66.95 |
Day's Range | 66.81 - 67.76 |
52 Week Range | 43.56 - 72.51 |
Volume | 6,357,688 |
Market Cap | 88.37B |
PE Ratio (TTM) | 15.95 |
EPS (TTM) | 4.2 |
Dividend & Yield | 2.660 (3.97%) |
1 Month Average Volume | 10,996,143 |
Chart
About CVS Health Corp (CVS)
CVS Health Corp is a diversified healthcare company that operates a vast network of retail pharmacies, providing prescription medications, over-the-counter products, and health and wellness services. In addition to its retail operations, CVS Health also offers pharmacy benefit management services, helping manage prescription drug costs for businesses and health plans. The company is involved in providing health insurance and health services through its various divisions, including a growing presence in digital health solutions and immunization services. By integrating pharmacy services with healthcare delivery, CVS Health aims to enhance patient care and improve health outcomes across the communities it serves. Read More
News & Press Releases
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Via StockStory · May 9, 2025
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a” (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) [NYSE: CVS]. (Please see below for a detailed listing of the companies.)
By AM Best · Via Business Wire · May 8, 2025
With uncertainty around tariffs still lingering, investors may want to add some reliable dividend income to their portfolio.
Via The Motley Fool · May 7, 2025
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?
Via MarketBeat · May 6, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 11.1%. This drop was worse than the S&P 500’s 1.7% loss.
Via StockStory · May 5, 2025
Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.
Via Stocktwits · May 4, 2025
Via Benzinga · May 2, 2025
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.
Via Benzinga · May 2, 2025
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
Via The Motley Fool · May 2, 2025
Via The Motley Fool · May 2, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · May 1, 2025
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · May 1, 2025
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives.
Via Benzinga · May 1, 2025
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · May 1, 2025
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced trade tariffs on April 2.
Via Benzinga · May 1, 2025
Via Benzinga · May 1, 2025
CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare performance.
Via Benzinga · May 1, 2025
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session.
Via Chartmill · May 1, 2025
Diversified healthcare company CVS Health (NYSE:CVS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 7% year on year to $94.59 billion. Its non-GAAP profit of $2.25 per share was 34.6% above analysts’ consensus estimates.
Via StockStory · May 1, 2025
The company now expects full-year adjusted EPS in the range of $6.00 to $6.20, up from its previous guidance of $5.75 to $6.00.
Via Stocktwits · May 1, 2025
Diversified healthcare company CVS Health (NYSE:CVS)
will be announcing earnings results tomorrow morning. Here’s what to expect.
Via StockStory · April 30, 2025
Jim Cramer is preparing investors for another action-packed week on Wall Street, packed with earnings reports from major tech players and key economic updates.
Via Benzinga · April 27, 2025